Oral Amiodarone Dosing for Hemodynamically Stable Pediatric Supraventricular Tachycardia
For a hemodynamically stable child with supraventricular tachycardia, amiodarone should be considered only after vagal maneuvers and adenosine have failed, and expert consultation is strongly recommended before administration. 1, 2
Initial Management Approach
Before considering amiodarone, the treatment algorithm should proceed as follows:
- First-line: Attempt vagal stimulation unless the patient is hemodynamically unstable 1, 2
- Second-line: Adenosine remains the preferred medication for pediatric SVT with a pulse 3
- Third-line: Consider amiodarone or procainamide only for SVT unresponsive to vagal maneuvers and adenosine 1, 2
Oral Amiodarone Dosing Regimen
When oral amiodarone is indicated for hemodynamically stable pediatric SVT:
Loading Phase
Loading dose: 10-15 mg/kg/day for 7-10 days 4
- Some protocols use 5 mg/kg once daily for 10 days 5
- Higher loading doses (20 mg/kg/day) have been used but are associated with increased QT prolongation 6
- The drug should be given in divided doses during the loading phase
Maintenance Phase
Maintenance dose: 5 mg/kg/day (or 250 mg/m²/day) 4, 7
- Continue for 6-12 months before considering discontinuation 7
- Some protocols reduce to 200-400 mg/day in older children/adolescents 8
Critical Considerations
When to Use Amiodarone
Amiodarone is particularly appropriate for:
- SVT refractory to first-line agents (digoxin, beta-blockers) 6, 7
- Wolff-Parkinson-White syndrome with recurrent SVT 7, 9
- Patients with congenital heart disease or ventricular dysfunction 6
Important caveat: The 2015 AHA guidelines emphasize that for hemodynamically stable patients, expert consultation is strongly recommended prior to amiodarone administration 1, 2. This reflects the drug's long half-life, potential drug interactions, and need for specialized monitoring 4.
Efficacy Data
Research demonstrates high efficacy in pediatric populations:
- 96.5% effectiveness when used alone or with digoxin 7
- 100% rhythm control achieved in one infant series 6
- 80% effectiveness in refractory arrhythmias 5
Safety Profile in Children
Amiodarone has proven safer in children than adults, with significantly lower rates of serious adverse effects 6, 7:
- No proarrhythmia reported in pediatric series 7
- Thyroid dysfunction: transient TSH elevation in approximately 10% of patients 7
- Photosensitivity: occurs but typically mild 10
- Hepatotoxicity and pulmonary toxicity: rare in short-term pediatric use 8
Monitoring Requirements
During oral amiodarone therapy, monitor:
- Continuous ECG monitoring during initiation 4
- QT interval (watch for prolongation) 6
- Thyroid function tests (baseline and periodic) 7
- Liver enzymes 5
- Growth and development (remain normal in most cases) 6
Contraindications
Do not use amiodarone in children with:
- Severe sinus node dysfunction 4
- Marked sinus bradycardia 4
- Second- or third-degree AV block (unless pacemaker present) 4
Drug Interactions
Critical interaction: Should not be combined with procainamide or other QT-prolonging drugs without expert consultation 4
Comparison with Alternative Agents
When amiodarone fails or is not tolerated, flecainide may be more effective as a second-line agent. In crossover studies, 80% of patients who failed amiodarone achieved success when switched to flecainide, compared to only 40% success when switching from flecainide to amiodarone 11.
Duration of Therapy
- Maintain prophylactic therapy for 6-12 months 7
- In "idiopathic" ventricular tachycardia, consider 2 years of treatment for potential cure 10
- Approximately 68% of infants remain arrhythmia-free after discontinuation 6
The evidence strongly supports amiodarone as highly effective and safe for pediatric SVT when used appropriately, but its use in hemodynamically stable patients should be reserved for refractory cases and requires cardiology consultation. 1, 2, 6, 7